Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016 (2016), Article ID 3481371, 13 pages
http://dx.doi.org/10.1155/2016/3481371
Review Article

Deubiquitinases: Novel Therapeutic Targets in Immune Surveillance?

1Manchester Collaborative Centre for Inflammation Research, University of Manchester, 46 Grafton Street, Manchester M13 9NT, UK
2Department of Microbiology and Cell Science, College of Agricultural and Life Sciences, University of Florida, 1355 Museum Drive, Gainesville, FL 32611-0700, USA

Received 24 March 2016; Revised 1 June 2016; Accepted 4 July 2016

Academic Editor: Luca Cantarini

Copyright © 2016 Gloria Lopez-Castejon and Mariola J. Edelmann. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Komander and M. Rape, “The ubiquitin code,” Annual Review of Biochemistry, vol. 81, pp. 203–229, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. Z. M. Eletr and K. D. Wilkinson, “Regulation of proteolysis by human deubiquitinating enzymes,” Biochimica et Biophysica Acta (BBA)—Molecular Cell Research, vol. 1843, no. 1, pp. 114–128, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. J.-M. Yuk, T. S. Kim, S. Y. Kim et al., “Orphan nuclear receptor ERRα controls macrophage metabolic signaling and A20 expression to negatively regulate TLR-induced inflammation,” Immunity, vol. 43, no. 1, pp. 80–92, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. K.-H. Lim, S. Ramakrishna, and K.-H. Baek, “Molecular mechanisms and functions of cytokine-inducible deubiquitinating enzymes,” Cytokine and Growth Factor Reviews, vol. 24, no. 5, pp. 427–431, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. Z. Xu, Y. Zheng, Y. Zhu, X. Kong, and L. Hu, “Evidence for OTUD-6B participation in B lymphocytes cell cycle after cytokine stimulation,” PLoS ONE, vol. 6, no. 1, Article ID e14514, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Niu, Y. Shi, J. Xue et al., “USP10 inhibits genotoxic NF-κB activation by MCPIP1-facilitated deubiquitination of NEMO,” EMBO Journal, vol. 32, no. 24, pp. 3206–3219, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. A. C. Faesen, A. M. G. Dirac, A. Shanmugham, H. Ovaa, A. Perrakis, and T. K. Sixma, “Mechanism of USP7/HAUSP activation by its C-Terminal ubiquitin-like domain and allosteric regulation by GMP-synthetase,” Molecular Cell, vol. 44, no. 1, pp. 147–159, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. M. A. Villamil, J. Chen, Q. Liang, and Z. Zhuang, “A noncanonical cysteine protease USP1 is activated through active site modulation by USP1-associated factor 1,” Biochemistry, vol. 51, no. 13, pp. 2829–2839, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. S. M. B. Nijman, T. T. Huang, A. M. G. Dirac et al., “The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway,” Molecular Cell, vol. 17, no. 3, pp. 331–339, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. A. E. Sims, E. Spiteri, R. J. Sims III et al., “FANCI is a second monoubiquitinated member of the Fanconi anemia pathway,” Nature Structural and Molecular Biology, vol. 14, no. 6, pp. 564–567, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. B. M. Kessler and M. J. Edelmann, “PTMs in conversation: activity and function of deubiquitinating enzymes regulated via post-translational modifications,” Cell Biochemistry and Biophysics, vol. 60, no. 1-2, pp. 21–38, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. W. Reiley, M. Zhang, X. Wu, E. Granger, and S.-C. Sun, “Regulation of the deubiquitinating enzyme CYLD by IκB kinase gamma-dependent phosphorylation,” Molecular and Cellular Biology, vol. 25, no. 10, pp. 3886–3895, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. S. I. Gringhuis, T. M. Kaptein, B. A. Wevers, A. W. Mesman, and T. B. H. Geijtenbeek, “Fucose-specific DC-SIGN signalling directs T helper cell type-2 responses via IKKε-and CYLD-dependent Bcl3 activation,” Nature Communications, vol. 5, article 3898, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. X. M. Cotto-Rios, M. Békés, J. Chapman, B. Ueberheide, and T. T. Huang, “Deubiquitinases as a signaling target of oxidative stress,” Cell Reports, vol. 2, no. 6, pp. 1475–1484, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. J.-G. Lee, K. Baek, N. Soetandyo, and Y. Ye, “Reversible inactivation of deubiquitinases by reactive oxygen species in vitro and in cells,” Nature Communications, vol. 4, article 1568, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Trinchieri and A. Sher, “Cooperation of Toll-like receptor signals in innate immune defence,” Nature Reviews Immunology, vol. 7, no. 3, pp. 179–190, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. M. J. Jiménez-Dalmaroni, M. E. Gerswhin, and I. E. Adamopoulos, “The critical role of toll-like receptors—from microbial recognition to autoimmunity: a comprehensive review,” Autoimmunity Reviews, vol. 15, no. 1, pp. 1–8, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. E. J. Hennessy, A. E. Parker, and L. A. J. O'Neill, “Targeting Toll-like receptors: emerging therapeutics?” Nature Reviews Drug Discovery, vol. 9, no. 4, pp. 293–307, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. P.-H. Tseng, A. Matsuzawa, W. Zhang, T. Mino, D. A. A. Vignali, and M. Karin, “Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines,” Nature Immunology, vol. 11, no. 1, pp. 70–75, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. I. E. Wertz and V. M. Dixit, “Signaling to NF-kappaB: regulation by ubiquitination,” Cold Spring Harbor Perspectives in Biology, vol. 2, no. 3, Article ID a003350, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. I. E. Wartz, K. M. O'Rourke, H. Zhou et al., “De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling,” Nature, vol. 430, no. 7000, pp. 694–699, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. B. Skaug, J. Chen, F. Du, J. He, A. Ma, and Z. J. Chen, “Direct, noncatalytic mechanism of IKK inhibition by A20,” Molecular Cell, vol. 44, no. 4, pp. 559–571, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Fulda, K. Rajalingam, and I. Dikic, “Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications,” EMBO Molecular Medicine, vol. 4, no. 7, pp. 545–556, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Colleran, P. E. Collins, C. O'Carroll et al., “Deubiquitination of NF-kappaB by Ubiquitin-Specific Protease-7 promotes transcription,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 2, pp. 618–623, 2013. View at Google Scholar
  25. T. Li, J. Guan, S. Li, X. Zhang, and X. Zheng, “HSCARG downregulates NF-κB signaling by interacting with USP7 and inhibiting NEMO ubiquitination,” Cell Death and Disease, vol. 5, no. 5, Article ID e1230, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. W. Wang, X. Huang, H.-B. Xin, M. Fu, A. Xue, and Z.-H. Wu, “TRAF family member-associated NF-κB activator (TANK) inhibits genotoxic nuclear factor κB activation by facilitating deubiquitinase USP10-dependent deubiquitination of TRAF6 ligase,” The Journal of Biological Chemistry, vol. 290, no. 21, pp. 13372–13385, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. K. J. Ritchie, C. S. Hahn, K. I. Kim et al., “Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection,” Nature Medicine, vol. 10, no. 12, pp. 1374–1378, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. Z. Yang, H. Xian, J. Hu et al., “USP18 negatively regulates NF-κB signaling by targeting TAK1 and NEMO for deubiquitination through distinct mechanisms,” Scientific Reports, vol. 5, Article ID 12738, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. G. Chen, M. H. Shaw, Y.-G. Kim, and G. Nuñez, “NOD-like receptors: role in innate immunity and inflammatory disease,” Annual Review of Pathology: Mechanisms of Disease, vol. 4, pp. 365–398, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. R. B. Damgaard, U. Nachbur, M. Yabal et al., “The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity,” Molecular Cell, vol. 46, no. 6, pp. 746–758, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. M. J. M. Bertrand, K. Doiron, K. Labbé, R. G. Korneluk, P. A. Barker, and M. Saleh, “Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2,” Immunity, vol. 30, no. 6, pp. 789–801, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. A. M. Ver Heul, C. A. Fowler, S. Ramaswamy, and R. C. Piper, “Ubiquitin regulates caspase recruitment domain-mediated signaling by nucleotide-binding oligomerization domain-containing proteins NOD1 and NOD2,” The Journal of Biological Chemistry, vol. 288, no. 10, pp. 6890–6902, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Zurek, I. Schoultz, A. Neerincx et al., “TRIM27 negatively regulates NOD2 by ubiquitination and proteasomal degradation,” PLoS ONE, vol. 7, no. 7, Article ID e41255, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. O. Hitotsumatsu, R.-C. Ahmad, R. Tavares et al., “The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals,” Immunity, vol. 28, no. 3, pp. 381–390, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. B. K. Fiil, R. B. Damgaard, S. A. Wagner et al., “OTULIN restricts Met1-linked ubiquitination to control innate immune signaling,” Molecular Cell, vol. 50, no. 6, pp. 818–830, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. E. Latz, T. S. Xiao, and A. Stutz, “Activation and regulation of the inflammasomes,” Nature Reviews Immunology, vol. 13, no. 6, pp. 397–411, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. R. Muñoz-Planillo, P. Kuffa, G. Martínez-Colón, B. Smith, T. Rajendiran, and G. Núñez, “K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter,” Immunity, vol. 38, no. 6, pp. 1142–1153, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Yan, W. Jiang, L. Liu et al., “Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome,” Cell, vol. 160, no. 1-2, pp. 62–73, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Han, T. B. Lear, J. A. Jerome et al., “Lipopolysaccharide primes the NALP3 inflammasome by inhibiting its ubiquitination and degradation mediated by the SCFFBXL2 E3 ligase,” The Journal of Biological Chemistry, vol. 290, no. 29, pp. 18124–18133, 2015. View at Publisher · View at Google Scholar
  40. Y. Hu, K. Mao, Y. Zeng et al., “Tripartite-motif protein 30 negatively regulates NLRP3 inflammasome activation by modulating reactive oxygen species production,” The Journal of Immunology, vol. 185, no. 12, pp. 7699–7705, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. L. Weng, H. Mitoma, C. Tricot et al., “The E3 ubiquitin ligase tripartite motif 33 is essential for cytosolic RNA-Induced NLRP3 inflammasome activation,” The Journal of Immunology, vol. 193, no. 7, pp. 3676–3682, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. J. E. Vince, W. W.-L. Wong, I. Gentle et al., “Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-1 activation,” Immunity, vol. 36, no. 2, pp. 215–227, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. K. Labbé, C. R. McIntire, K. Doiron, P. M. Leblanc, and M. Saleh, “Cellular inhibitors of apoptosis proteins cIAP1 and cIAP2 are required for efficient caspase-1 activation by the inflammasome,” Immunity, vol. 35, no. 6, pp. 897–907, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. N. Van Opdenbosch, P. Gurung, L. Vande Walle, A. Fossoul, T.-D. Kanneganti, and M. Lamkanfi, “Activation of the NLRP1b inflammasome independently of ASC-mediated caspase-1 autoproteolysis and speck formation,” Nature Communications, vol. 5, article 3209, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. C.-S. Shi, K. Shenderov, N.-N. Huang et al., “Activation of autophagy by inflammatory signals limits IL-1β production by targeting ubiquitinated inflammasomes for destruction,” Nature Immunology, vol. 13, no. 3, pp. 255–263, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Guan, C. Wei, Z. Zheng et al., “MAVS promotes inflammasome activation by targeting ASC for K63-linked ubiquitination via the E3 Ligase TRAF3,” The Journal of Immunology, vol. 194, no. 10, pp. 4880–4890, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. H.-W. Chiu, C.-H. Chen, J.-N. Chang, C.-H. Chen, and Y.-H. Hsu, “Far-infrared promotes burn wound healing by suppressing NLRP3 inflammasome caused by enhanced autophagy,” Journal of Molecular Medicine, vol. 94, no. 7, pp. 809–819, 2016. View at Publisher · View at Google Scholar · View at Scopus
  48. M. A. Rodgers, J. W. Bowman, H. Fujita et al., “The linear ubiquitin assembly complex (LUBAC) is essential for NLRP3 inflammasome activation,” Journal of Experimental Medicine, vol. 211, no. 7, pp. 1333–1347, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. P. Gurung, M. Lamkanfi, and T.-D. Kanneganti, “Cutting edge: SHARPIN is required for optimal NLRP3 inflammasome activation,” The Journal of Immunology, vol. 194, no. 5, pp. 2064–2067, 2015. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Juliana, T. Fernandes-Alnemri, S. Kang, A. Farias, F. Qin, and E. S. Alnemri, “Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation,” The Journal of Biological Chemistry, vol. 287, no. 43, pp. 36617–36622, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. B. F. Py, M.-S. Kim, H. Vakifahmetoglu-Norberg, and J. Yuan, “Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity,” Molecular Cell, vol. 49, no. 2, pp. 331–338, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. G. Lopez-Castejon, N. M. Luheshi, V. Compan et al., “Deubiquitinases regulate the activity of caspase-1 and interleukin-1β secretion via assembly of the inflammasome,” The Journal of Biological Chemistry, vol. 288, no. 4, pp. 2721–2733, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. I. Hwang, E. Lee, S.-A. Jeon, and J.-W. Yu, “Histone deacetylase 6 negatively regulates NLRP3 inflammasome activation,” Biochemical and Biophysical Research Communications, vol. 467, no. 4, pp. 973–978, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. C. Juliana, T. Fernandes-Alnemri, J. Wu et al., “Anti-inflammatory compounds parthenolide and bay 11-7082 are direct inhibitors of the inflammasome,” The Journal of Biological Chemistry, vol. 285, no. 13, pp. 9792–9802, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Strickson, D. G. Campbell, C. H. Emmerich et al., “The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system,” Biochemical Journal, vol. 451, no. 3, pp. 427–437, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. M. S. Ritorto, R. Ewan, A. B. Perez-Oliva et al., “Screening of DUB activity and specificity by MALDI-TOF mass spectrometry,” Nature Communications, vol. 5, article 4763, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. B. H. Duong, M. Onizawa, J. A. Oses-Prieto et al., “A20 restricts ubiquitination of pro-interleukin-1β protein complexes and suppresses NLRP3 inflammasome activity,” Immunity, vol. 42, no. 1, pp. 55–67, 2015. View at Publisher · View at Google Scholar · View at Scopus
  58. L. Vande Walle, N. Van Opdenbosch, P. Jacques et al., “Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis,” Nature, vol. 512, no. 1, pp. 69–73, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. M. J. Edelmann and B. M. Kessler, “Ubiquitin and ubiquitin-like specific proteases targeted by infectious pathogens: emerging patterns and molecular principles,” Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, vol. 1782, no. 12, pp. 809–816, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. A. S. Neish, A. T. Gewirtz, H. Zeng et al., “Prokaryotic regulation of epithelial responses by inhibition of IκB-α ubiquitination,” Science, vol. 289, no. 5484, pp. 1560–1563, 2000. View at Publisher · View at Google Scholar · View at Scopus
  61. L. S. Collier-Hyams, H. Zeng, J. Sun et al., “Cutting edge: Salmonella AvrA effector inhibits the key proinflammatory, anti-apoptotic NF-κB pathway,” The Journal of Immunology, vol. 169, no. 6, pp. 2846–2850, 2002. View at Publisher · View at Google Scholar · View at Scopus
  62. Z. Ye, E. O. Petrof, D. Boone, E. C. Claud, and J. Sun, “Salmonella effector AvrA regulation of colonic epithelial cell inflammation by deubiquitination,” The American Journal of Pathology, vol. 171, no. 3, pp. 882–892, 2007. View at Publisher · View at Google Scholar
  63. R. Lu, S. Wu, Y.-G. Zhang et al., “Enteric bacterial protein AvrA promotes colonic tumorigenesis and activates colonic beta-catenin signaling pathway,” Oncogenesis, vol. 3, article e105, 2014. View at Publisher · View at Google Scholar · View at Scopus
  64. S. Misaghi, Z. R. Balsara, A. Catic, E. Spooner, H. L. Ploegh, and M. N. Starnbach, “Chlamydia trachomatis-derived deubiquitinating enzymes in mammalian cells during infection,” Molecular Microbiology, vol. 61, no. 1, pp. 142–150, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. G. Le Negrate, A. Krieg, B. Faustin et al., “ChlaDub1 of Chlamydia trachomatis suppresses NF-κB activation and inhibits IκBα ubiquitination and degradation,” Cellular Microbiology, vol. 10, no. 9, pp. 1879–1892, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. E. Kummari, N. Alugubelly, C. Y. Hsu, B. Dong, B. Nanduri, and M. J. Edelmann, “Activity-based proteomic profiling of deubiquitinating enzymes in salmonella-infected macrophages leads to identification of putative function of UCH-L5 in inflammasome regulation,” PLoS ONE, vol. 10, no. 8, Article ID e0135531, 2015. View at Publisher · View at Google Scholar
  67. H. Yen, N. Sugimoto, and T. Tobe, “Enteropathogenic Escherichia coli uses NleA to inhibit NLRP3 inflammasome activation,” PLoS Pathogens, vol. 11, no. 9, Article ID e1005121, 23 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  68. J. Heideker and I. E. Wertz, “DUBs, the regulation of cell identity and disease,” Biochemical Journal, vol. 465, no. 1, pp. 1–26, 2015. View at Publisher · View at Google Scholar · View at Scopus
  69. T. R. Brummelkamp, S. M. B. Nijman, A. M. G. Dirac, and R. Bernards, “Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB,” Nature, vol. 424, no. 6950, pp. 797–801, 2003. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Kovalenko, C. Chable-Bessia, G. Cantarella, A. Israël, D. Wallach, and G. Courtois, “The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination,” Nature, vol. 424, no. 6950, pp. 801–805, 2003. View at Publisher · View at Google Scholar · View at Scopus
  71. E. Trompouki, E. Hatzivassillou, T. Tsichritzis, H. Farmer, A. Ashworth, and G. Mosialos, “CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members,” Nature, vol. 424, no. 6950, pp. 793–796, 2003. View at Publisher · View at Google Scholar · View at Scopus
  72. J. Zhang, B. Stirling, S. T. Temmerman et al., “Impaired regulation of NF-κB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice,” The Journal of Clinical Investigation, vol. 116, no. 11, pp. 3042–3049, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. G. Courtois, “Tumor suppressor CYLD: negative regulation of NF-κB signaling and more,” Cellular and Molecular Life Sciences, vol. 65, no. 7-8, pp. 1123–1132, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. M. J. Schuijs, M. A. Willart, K. Vergote et al., “Farm dust and endotoxin protect against allergy through A20 induction in lung epithelial cells,” Science, vol. 349, no. 6252, pp. 1106–1110, 2015. View at Publisher · View at Google Scholar · View at Scopus
  75. A. Ma and B. A. Malynn, “A20: linking a complex regulator of ubiquitylation to immunity and human disease,” Nature Reviews Immunology, vol. 12, no. 11, pp. 774–785, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. D. L. Boone, E. E. Turer, E. G. Lee et al., “The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses,” Nature Immunology, vol. 5, no. 10, pp. 1052–1060, 2004. View at Publisher · View at Google Scholar · View at Scopus
  77. X. Liu, H. Li, B. Zhong et al., “Usp18 inhibits NF-κB and NFAT activation during Th17 differentiation by deubiquitinating the TAK1-TAB1 complex,” The Journal of Experimental Medicine, vol. 210, no. 8, pp. 1575–1590, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. C. L. Brooks, M. Li, M. Hu, Y. Shi, and W. Gu, “The p53—Mdm2—HAUSP complex is involved in p53 stabilization by HAUSP,” Oncogene, vol. 26, no. 51, pp. 7262–7266, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. C. Boutell, M. Canning, A. Orr, and R. D. Everett, “Reciprocal activities between herpes simplex virus type 1 regulatory protein ICP0, a ubiquitin E3 ligase, and ubiquitin-specific protease USP7,” Journal of Virology, vol. 79, no. 19, pp. 12342–12354, 2005. View at Publisher · View at Google Scholar · View at Scopus
  80. M. N. Holowaty and L. Frappier, “HAUSP/USP7 as an Epstein-Barr virus target,” Biochemical Society Transactions, vol. 32, no. 5, pp. 731–732, 2004. View at Publisher · View at Google Scholar · View at Scopus
  81. S. Chavoshi, O. Egorova, I. K. Lacdao, S. Farhadi, Y. Sheng, and V. Saridakis, “Identification of kaposi sarcoma herpesvirus (KSHV) vIRF1 protein as a novel interaction partner of human deubiquitinase USP7,” Journal of Biological Chemistry, vol. 291, no. 12, pp. 6281–6291, 2016. View at Publisher · View at Google Scholar
  82. N. Kon, Y. Kobayashi, M. Li, C. L. Brooks, T. Ludwig, and W. Gu, “Inactivation of HAUSP in vivo modulates p53 function,” Oncogene, vol. 29, no. 9, pp. 1270–1279, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. D. H. Adams, N. Ruzehaji, X. L. Strudwick et al., “Attenuation of Flightless I, an actin-remodelling protein, improves burn injury repair via modulation of transforming growth factor (TGF)-β1 and TGF-β3,” British Journal of Dermatology, vol. 161, no. 2, pp. 326–336, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. S. T. Nawrocki, P. Griffin, K. R. Kelly, and J. S. Carew, “MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy,” Expert Opinion on Investigational Drugs, vol. 21, no. 10, pp. 1563–1573, 2012. View at Publisher · View at Google Scholar · View at Scopus
  85. S. T. Beug, V. A. Tang, E. C. LaCasse et al., “Smac mimetics and innate immune stimuli synergize to promote tumor death,” Nature Biotechnology, vol. 32, no. 2, pp. 182–190, 2014. View at Publisher · View at Google Scholar · View at Scopus
  86. P. Farshi, R. R. Deshmukh, J. O. Nwankwo et al., “Deubiquitinases (DUBs) and DUB inhibitors: a patent review,” Expert Opinion on Therapeutic Patents, vol. 25, no. 10, pp. 1191–1208, 2015. View at Publisher · View at Google Scholar · View at Scopus
  87. M. Kemp, “Recent advances in the discovery of deubiquitinating enzyme inhibitors,” Progress in Medicinal Chemistry, vol. 55, pp. 149–192, 2016. View at Publisher · View at Google Scholar
  88. Y.-H. Fan, J. Cheng, S. A. Vasudevan et al., “USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis,” Cell Death and Disease, vol. 4, no. 10, article e867, 2013. View at Publisher · View at Google Scholar · View at Scopus
  89. X. He, Y. Li, C. Li et al., “USP2a negatively regulates IL-1β- and virus-induced NF-κB activation by deubiquitinating TRAF6,” Journal of Molecular Cell Biology, vol. 5, no. 1, pp. 39–47, 2013. View at Publisher · View at Google Scholar · View at Scopus
  90. Y.-H. Fan, Y. Yu, R.-F. Mao et al., “USP4 targets TAK1 to downregulate TNFα-induced NF-κB activation,” Cell Death and Differentiation, vol. 18, no. 10, pp. 1547–1560, 2011. View at Publisher · View at Google Scholar · View at Scopus
  91. (IMPC), I.M.P.C., http://www.mousephenotype.org/data/genes/MGI:894652.
  92. K. Schweitzer, P. M. Bozko, W. Dubiel, and M. Naumann, “CSN controls NF-κB by deubiquitinylation of IκBα,” The EMBO Journal, vol. 26, no. 6, pp. 1532–1541, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. P. Y. Jean-Charles, L. Zhang, J. Wu et al., “Ubiquitin-specific protease 20 regulates the reciprocal functions of β-arrestin2 in toll-like receptor 4-promoted nuclear factor κB (NFκB) activation,” Journal of Biological Chemistry, vol. 291, no. 14, pp. 7450–7464, 2016. View at Publisher · View at Google Scholar
  94. G. Xu, X. Tan, H. Wang et al., “Ubiquitin-specific peptidase 21 inhibits tumor necrosis factor α-induced nuclear factor κB activation via binding to and deubiquitinating receptor-interacting protein 1,” Journal of Biological Chemistry, vol. 285, no. 2, pp. 969–978, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. Y. Fan, R. Mao, Y. Yu et al., “USP21 negatively regulates antiviral response by acting as a RIG-I deubiquitinase,” Journal of Experimental Medicine, vol. 211, no. 2, pp. 313–328, 2014. View at Publisher · View at Google Scholar · View at Scopus
  96. B. Zhong, X. Liu, X. Wang et al., “Ubiquitin-specific protease 25 regulates TLR4-dependent innate immune responses through deubiquitination of the adaptor protein TRAF3,” Science Signaling, vol. 6, no. 275, article ra35, 2013. View at Publisher · View at Google Scholar · View at Scopus
  97. D. Lin, M. Zhang, M.-X. Zhang et al., “Induction of USP25 by viral infection promotes innate antiviral responses by mediating the stabilization of TRAF3 and TRAF6,” Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 36, pp. 11324–11329, 2015. View at Publisher · View at Google Scholar · View at Scopus
  98. C. Tzimas, G. Michailidou, M. Arsenakis, E. Kieff, G. Mosialos, and E. G. Hatzivassiliou, “Human ubiquitin specific protease 31 is a deubiquitinating enzyme implicated in activation of nuclear factor-κB,” Cellular Signalling, vol. 18, no. 1, pp. 83–92, 2006. View at Publisher · View at Google Scholar · View at Scopus
  99. P. Draber, S. Kupka, M. Reichert et al., “LUBAC-recruited CYLD and A20 regulate gene activation and cell death by exerting opposing effects on linear ubiquitin in signaling complexes,” Cell Reports, vol. 13, no. 10, pp. 2258–2272, 2015. View at Publisher · View at Google Scholar
  100. K. Verhelst, I. Carpentier, M. Kreike et al., “A20 inhibits LUBAC-mediated NF-κB activation by binding linear polyubiquitin chains via its zinc finger 7,” The EMBO Journal, vol. 31, no. 19, pp. 3845–3855, 2012. View at Publisher · View at Google Scholar · View at Scopus
  101. K. Enesa, M. Zakkar, H. Chaudhury et al., “NF-κB suppression by the deubiquitinating enzyme cezanne: a novel negative feedback loop in pro-inflammatory signaling,” Journal of Biological Chemistry, vol. 283, no. 11, pp. 7036–7045, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. H. Hu, G. C. Brittain, J.-H. Chang et al., “OTUD7B controls non-canonical NF-κB activation through deubiquitination of TRAF3,” Nature, vol. 494, no. 7437, pp. 371–374, 2013. View at Publisher · View at Google Scholar · View at Scopus
  103. V. Schaeffer, M. Akutsu, M. H. Olma, L. C. Gomes, M. Kawasaki, and I. Dikic, “Binding of OTULIN to the PUB domain of HOIP controls NF-κB signaling,” Molecular Cell, vol. 54, no. 3, pp. 349–361, 2014. View at Publisher · View at Google Scholar · View at Scopus
  104. E. Rivkin, S. M. Almeida, D. F. Ceccarelli et al., “The linear ubiquitin-specific deubiquitinase gumby regulates angiogenesis,” Nature, vol. 498, no. 7454, pp. 318–324, 2013. View at Publisher · View at Google Scholar · View at Scopus
  105. P. R. Elliott, S. V. Nielsen, P. Marco-Casanova et al., “Molecular basis and regulation of OTULIN-LUBAC interaction,” Molecular Cell, vol. 54, no. 3, pp. 335–348, 2014. View at Publisher · View at Google Scholar · View at Scopus
  106. S. Panda, J. A. Nilsson, and N. O. Gekara, “Deubiquitinase MYSM1 regulates innate immunity through inactivation of TRAF3 and TRAF6 complexes,” Immunity, vol. 43, no. 4, pp. 647–659, 2015. View at Publisher · View at Google Scholar · View at Scopus